VistaSeal
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $19,951 | 4 | 0 |
| 2022 | $14,008 | 4 | 0 |
| 2021 | $52,687 | 19 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $86,645 | 27 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects | Grifols Biologicals LLC | $66,695 | 0 |
| A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects | Grifols Therapeutics LLC | $19,951 | 0 |
Top Doctors Receiving Payments for VistaSeal
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $86,645 | 27 |
Manufacturing Companies
- Grifols Biologicals LLC $66,695
- Grifols Therapeutics LLC $19,951
Product Information
- Type Biological
- Total Payments $86,645
- Total Doctors 0
- Transactions 27
About VistaSeal
VistaSeal is a biological associated with $86,645 in payments to 0 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Grifols Biologicals LLC.
Payment data is available from 2021 to 2023. In 2023, $19,951 was paid across 4 transactions to 0 doctors.
The most common payment nature for VistaSeal is "Unspecified" ($86,645, 100.0% of total).
VistaSeal is associated with 2 research studies, including "A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols FS Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects" ($66,695).